Kiniksa Pharmaceuticals Ltd (KNSA) — Cash Flow Reinvestment Rate
Kiniksa Pharmaceuticals Ltd (KNSA) has a Cash Flow Reinvestment Rate of 0.64x as of March 2026, reinvesting $31.92 Million (capex $161.00K plus investments $-31.75 Million) from operating cash flow of $50.20 Million. Check how high is Kiniksa Pharmaceuticals Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Kiniksa Pharmaceuticals Ltd Cash Flow Reinvestment Rate (2022–2025)
Historical reinvestment intensity for Kiniksa Pharmaceuticals Ltd across 4 annual periods. Explore KNSA debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Kiniksa Pharmaceuticals Ltd (2022–2025)
Year-by-year capital reinvestment analysis for Kiniksa Pharmaceuticals Ltd. For live market cap and broader valuation context, see Kiniksa Pharmaceuticals Ltd market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 7.31x | $187.70 Million | $25.69 Million | $277.00K | ▲ +394.6% |
| 2024 | 1.48x | $37.95 Million | $25.69 Million | $277.00K | ▼ -65.8% |
| 2023 | 4.32x | $57.45 Million | $13.30 Million | $130.00K | ▲ +207.1% |
| 2022 | 1.41x | $8.17 Million | $5.81 Million | $105.00K | — |